You are here: Home » Companies » News
Business Standard

Cipla launches generic hepatitis C drug

About 12-18 million Indians are suffering from the disease while globally the number of patients is about 185 million

BS Reporter  |  Mumbai 

Cipla launches anti hepatitis drug

Drug maker Cipla on Monday announced the launch of a generic version of anti-hepatitis drug Ledipasvir-Sofosbuvir in the domestic market.

The drug is used for treating the hepatitis C virus. About 12-18 million Indians are suffering from it while globally the number is about 185 million.

Last year, pharma company Gilead Sciences signed non-exclusive licencing agreements with seven companies, including Cipla, for the manufacture and distribution of the drug in India.

Cipla also announced the launch of a patient support programme to create awareness amongst people and to cater to existing patients.

Managing Director and Global Chief Executive Officer Subhanu Saxena said, “The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus.”

Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients, Cipla said.

The company’s current portfolio includes over 1,500 products across therapeutic categories.

Cipla was trading at Rs 646.15, up 0.62 per cent, on the BSE.

(With inputs from agencies)

First Published: Tue, December 22 2015. 00:47 IST